Premium
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis
Author(s) -
Gené E.,
Calvet X.,
Azagra R.,
Gisbert J. P.
Publication year - 2003
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2003.01566.x
Subject(s) - medicine , helicobacter pylori , metronidazole , odds ratio , amoxicillin , regimen , confidence interval , proton pump inhibitor , meta analysis , clarithromycin , gastroenterology , esomeprazole , adverse effect , antibiotics , microbiology and biotechnology , biology
Summary Background: Triple therapy (proton pump inhibitor, clarithromycin and amoxicillin or an imidazole) is the first‐line treatment for Helicobacter pylori infection. However, the effectiveness of triple therapy is decreasing due to the increase in antibiotic resistance. Quadruple therapy (proton pump inhibitor, tetracycline, metronidazole and a bismuth salt) is a very effective regimen even in areas of high prevalence of antibiotic resistance, and may be an alternative first‐line treatment. Aim: To compare triple vs. quadruple therapy for the first‐line treatment of H. pylori infection. Methods: An extensive literature search was performed to identify randomized trials comparing triple vs. quadruple therapy. Selected trials were included in a meta‐analysis using Review Manager 4.1. Results: Four studies met the inclusion criteria. Eradication rates with quadruple therapy were slightly higher in both the intention‐to‐treat (81% vs. 78%; odds ratio, 0.83; 95% confidence interval, 0.61–1.14) and per protocol (88% vs. 85%; odds ratio, 0.81; 95% confidence interval, 0.55–1.20) analysis, although the differences were not statistically significant. Nor were there significant differences in compliance or adverse effects between the therapies. Conclusion: Triple and quadruple therapies seem to be roughly equivalent in terms of effectiveness, compliance and side‐effects profile when administered as first‐line treatment for H. pylori infection.